Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia
Abstract
Abstract Autologous second-generation CD7-directed chimeric antigen receptor T cells, expressing an anti-CD7 protein expression blocker to prevent self-killing fratricide, were infused in 3 pediatric/young adult patients with relapsed/refractory CD7+ acute myeloid leukemia, resulting in measurable residual disease negativity. The safety profile was favorable.
Article Details
Authors (18)
Marco Becilli
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Pietro Merli
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Mattia Algeri
IRCCS Ospedale Pediatrico Bambino Gesù Rome, Rome
Francesca Del Bufalo
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Daria Pagliara
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Valentina Bertaina
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Chiara Agrati
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Chiara Rosignoli
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Maria Giuseppina Cefalo
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Emilia Boccieri
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Stefano Di Cecca
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Laura Iaffaldano
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Yunqin Lee
4Discovery Sciences, MediSix Therapeutics, Singapore, Singapore
Biagio De Angelis
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Soheil Meshinchi
Concetta Quintarelli
1Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare, Bambino Gesù Children’s Hospital, Rome, Italy
Dario Campana
7Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Franco Locatelli
IRCCS Ospedale Pediatrico Bambino Gesù Rome, Rome